Company news

Invivyd, Inc. news in 2026

Invivyd, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 3, 2026

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

October 21, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

September 29, 2026

Invivyd to Participate in Upcoming September Investor Conferences

September 8, 2026

Invivyd Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

September 4, 2026

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

September 1, 2026

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 13, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 4, 2026

August 5, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2026

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

July 6, 2026

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

June 16, 2026

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Adminis...

June 8, 2026

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

May 31, 2026

Invivyd to Participate in Upcoming Investor Events

May 26, 2026

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

May 7, 2026

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

April 20, 2026

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

April 8, 2026

Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

April 6, 2026

Invivyd Announces Presentation at the World Vaccine Congress Washington

March 29, 2026

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

March 4, 2026

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

March 4, 2026

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

March 2, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 2, 2026

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

February 24, 2026

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

February 3, 2026

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

January 22, 2026

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

January 20, 2026

Adimab Records Another Year of Double-Digit Clinical Program Growth

January 13, 2026

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

January 8, 2026

Calls in 2026

Decks in 2026